Research
Hormonal
GLP-1 receptor agonists can trigger or exacerbate restrictive eating behaviors and food aversions, mimicking Avoidant/Restrictive Food Intake Disorder (ARFID), in patients with obesity and those with rare genetic disorders of obesity.
Be aware that GLP-1s can make you lose interest in food entirely. If you find yourself unable to eat enough to maintain your health, or if you develop strong aversions to specific foods, inform your doctor immediately. This may require dose reduction or discontinuation.
ModerateSupportsMEDIUM confidence
Such medications risk suppressing appetite excessively, which can potentially lead to conditions mimicking Avoidant/Restrictive Food Intake Disorder (ARFID)... [Case 1] reporting severe aversion to food to the point of consuming 400 Calories a day.
Why this rating
Based on case series and clinical observation.
Source
Highway to the danger zone? A cautionary account that GLP-1 receptor agonists may be too effective for unmonitored weight loss
Jesse Richards et al. · 2023
DOI 10.31234/osf.io/uxa78
case_series · n=6Cited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →